These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 24291021)

  • 1. Total soluble and endogenous secretory receptor for advanced glycation endproducts (RAGE) in IBD.
    Meijer B; Hoskin T; Ashcroft A; Burgess L; Keenan JI; Falvey J; Gearry RB; Day AS
    J Crohns Colitis; 2014 Jun; 8(6):513-20. PubMed ID: 24291021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of soluble receptor for advanced glycation endproducts (sRAGE) are higher in ulcerative colitis and correlate with disease activity.
    Yilmaz Y; Yonal O; Eren F; Atug O; Hamzaoglu HO
    J Crohns Colitis; 2011 Oct; 5(5):402-6. PubMed ID: 21939913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Circulating Level of Soluble Receptor for Advanced Glycation End Products Displays Different Patterns in Ulcerative Colitis and Crohn's Disease: A Cross-Sectional Study.
    Ciccocioppo R; Imbesi V; Betti E; Boccaccio V; Kruzliak P; Gallia A; Cangemi GC; Maffe GC; Vanoli A; Merante S; De Amici M; Falcone C; Klersy C; Corazza GR
    Dig Dis Sci; 2015 Aug; 60(8):2327-37. PubMed ID: 25757448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic levels of the anti-inflammatory decoy receptor soluble RAGE (receptor for advanced glycation end products) are decreased in dogs with inflammatory bowel disease.
    Heilmann RM; Otoni CC; Jergens AE; Grützner N; Suchodolski JS; Steiner JM
    Vet Immunol Immunopathol; 2014 Oct; 161(3-4):184-92. PubMed ID: 25183017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble receptor for advanced glycation endproducts is decreased in patients with juvenile idiopathic arthritis (ERA category) and inversely correlates with disease activity and S100A12 levels.
    Myles A; Viswanath V; Singh YP; Aggarwal A
    J Rheumatol; 2011 Sep; 38(9):1994-9. PubMed ID: 21724696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of insulin on the soluble receptor for advanced glycation end products (RAGE).
    Lam JK; Wang Y; Shiu SW; Wong Y; Betteridge DJ; Tan KC
    Diabet Med; 2013 Jun; 30(6):702-9. PubMed ID: 23432638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AGEs/sRAGE, a novel risk factor in the pathogenesis of end-stage renal disease.
    Prasad K; Dhar I; Zhou Q; Elmoselhi H; Shoker M; Shoker A
    Mol Cell Biochem; 2016 Dec; 423(1-2):105-114. PubMed ID: 27714575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two soluble isoforms of receptors for advanced glycation end products (RAGE) in carotid atherosclerosis: the difference of soluble and endogenous secretory RAGE.
    Moriya S; Yamazaki M; Murakami H; Maruyama K; Uchiyama S
    J Stroke Cerebrovasc Dis; 2014; 23(10):2540-2546. PubMed ID: 25282185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes.
    Katakami N; Matsuhisa M; Kaneto H; Matsuoka TA; Sakamoto K; Yasuda T; Umayahara Y; Kosugi K; Yamasaki Y
    Atherosclerosis; 2009 May; 204(1):288-92. PubMed ID: 18926539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes.
    Tan KCB; Chow WS; Tso AWK; Xu A; Tse HF; Hoo RLC; Betteridge DJ; Lam KSL
    Diabetologia; 2007 Sep; 50(9):1819-1825. PubMed ID: 17639302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble receptor for advanced glycation end products (sRAGE) and endogenous secretory RAGE (esRAGE) in amniotic fluid: modulation by infection and inflammation.
    Romero R; Espinoza J; Hassan S; Gotsch F; Kusanovic JP; Avila C; Erez O; Edwin S; Schmidt AM
    J Perinat Med; 2008; 36(5):388-98. PubMed ID: 18593373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The receptor for advanced glycation endproducts and its ligands in patients with myasthenia gravis.
    Moser B; Bekos C; Zimprich F; Nickl S; Klepetko W; Ankersmit J
    Biochem Biophys Res Commun; 2012 Mar; 420(1):96-101. PubMed ID: 22405771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble Forms and Ligands of the Receptor for Advanced Glycation End-Products in Patients with Acute Respiratory Distress Syndrome: An Observational Prospective Study.
    Jabaudon M; Blondonnet R; Roszyk L; Pereira B; Guérin R; Perbet S; Cayot S; Bouvier D; Blanchon L; Sapin V; Constantin JM
    PLoS One; 2015; 10(8):e0135857. PubMed ID: 26274928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4+ immune response as a potential biomarker of patient reported inflammatory bowel disease (IBD) activity.
    Brandhorst G; Weigand S; Eberle C; Raddatz D; Karaus M; Oellerich M; Walson PD
    Clin Chim Acta; 2013 Jun; 421():31-3. PubMed ID: 23485644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating levels of soluble receptor for advanced glycation end product are inversely associated with vascular calcification in patients on haemodialysis independent of S100A12 (EN-RAGE) levels.
    Kim HS; Chung W; Kim AJ; Ro H; Chang JH; Lee HH; Jung JY
    Nephrology (Carlton); 2013 Dec; 18(12):777-82. PubMed ID: 24124651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of serum sRAGE and esRAGE in women with normal pregnancy and preeclampsia.
    Kwon JH; Kim YH; Kwon JY; Park YW
    J Perinat Med; 2011 Sep; 39(5):507-13. PubMed ID: 21767223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes.
    Humpert PM; Djuric Z; Kopf S; Rudofsky G; Morcos M; Nawroth PP; Bierhaus A
    Cardiovasc Diabetol; 2007 Mar; 6():9. PubMed ID: 17343760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function.
    Gohda T; Tanimoto M; Moon JY; Gotoh H; Aoki T; Matsumoto M; Shibata T; Ohsawa I; Funabiki K; Tomino Y
    Diabetes Res Clin Pract; 2008 Aug; 81(2):196-201. PubMed ID: 18550199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease.
    Foell D; Kucharzik T; Kraft M; Vogl T; Sorg C; Domschke W; Roth J
    Gut; 2003 Jun; 52(6):847-53. PubMed ID: 12740341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of the plasma levels of soluble RAGE and endogenous secretory RAGE with oxidative stress in pre-diabetic patients.
    Huang M; Que Y; Shen X
    J Diabetes Complications; 2015 Apr; 29(3):422-6. PubMed ID: 25659638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.